TEL
71
2
TSCO
51
-2
TGNA
59
-5
KHC
13
-4
IPG
47
-3
DRI
54
-2
PG
48
-2
NTAP
64
-2
CME
61
2
NEE
50
-2
NWL
57
-4
HPQ
62
3
WHR
66
-7
EIX
70
-2
LYB
37
-2
M
31
-2
CI
58
-10
HSY
40
3
HRB
60
-6
JBHT
68
-4
TEL
71
2
TSCO
51
-2
TGNA
59
-5
KHC
13
-4
IPG
47
-3
DRI
54
-2
PG
48
-2
NTAP
64
-2
CME
61
2
NEE
50
-2
NWL
57
-4
HPQ
62
3
WHR
66
-7
EIX
70
-2
LYB
37
-2
M
31
-2
CI
58
-10
HSY
40
3
HRB
60
-6
JBHT
68
-4
Financhill
Back

Zevra Therapeutics Quote, Financials, Valuation and Earnings

Buy these stocks BEFORE President Trump returns to the Oval Office

See details on which stocks are poised to surge.
Buy
67

ZVRA
Zevra Therapeutics

Last Price:
8.65
Seasonality Move:
4.71%

7 Day Trial

ALL ACCESS PASS

$ 7

Write This Down: Tuesday at 2 p.m. ET!

Don't Miss Our LIVE Trade

Zevra Therapeutics Price Quote

$8.65
+0.08 (+0.93%)
(Updated: November 13, 2024 at 5:55 PM ET)

Zevra Therapeutics Key Stats

Buy
67
Zevra Therapeutics (ZVRA) is a Buy
Day range:
$8.35 - $9.09
52-week range:
$4.11 - $9.09
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
14.29
P/B ratio:
13.88%
Volume:
962.6K
Avg. volume:
695.5K
1-year change:
106.51%
Market cap:
$450.9M
Revenue:
$27.5M
EPS:
$-1.68

How Much Does Zevra Therapeutics Make?

Is Zevra Therapeutics Growing As A Company?

  • What Is Zevra Therapeutics's Growth Rate Quarterly?
    Quarterly YoY revenue growth is -0.47%
  • What Is Zevra Therapeutics's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Zevra Therapeutics Stock Price Performance

What Is Zevra Therapeutics 52-Week High & Low?

Zevra Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Zevra Therapeutics?

  • How Much Debt Does Zevra Therapeutics Have?
    Total long term debt quarterly is $58.3M
  • How Much Cash Does Zevra Therapeutics Have?
    Cash and short term investments quarterly total is $49.3M
  • What Is Zevra Therapeutics’s Book Value Per Share?
    Book value per share is 0.77

Is Zevra Therapeutics Cash Flow Positive?

  • What Is ZVRA Cash Flow From Operations?
    Cash flow from operations (TTM) is -$56.1M
  • What Is Zevra Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $47.8M
  • What Is Zevra Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$19.2M

Zevra Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    ZVRA return on invested capital is -68.51%
  • What Is Zevra Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is -46.14%
  • What Is ZVRA Return On Equity?
    ROE is a measure of profitability and is -117.77%

Zevra Therapeutics Earnings Date & Stock Price

Zevra Therapeutics Competitors

  • Who Are Zevra Therapeutics's Competitors?
    Below is a list of companies who compete with Zevra Therapeutics or are related in some way:
    • BioCardia Inc (BCDA)
    • Ionis Pharmaceuticals Inc (IONS)
    • Instil Bio Inc (TIL)
    • Vanda Pharmaceuticals Inc (VNDA)
    • Xeris Biopharma Holdings Inc (XERS)

Zevra Therapeutics Dividend Yield

Zevra Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -9.92%
Revenue: -47.47% 2.09%

Analyst Recommendations

Buy Recommendations: 4
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 20.43
Upside from Last Price: 138.37%

Major Shareholders

  • How many ZVRA shares are owned by institutional investors?
    30.8M ZVRA shares are owned by institutional investors
  • How many ZVRA shares are owned by insiders?
    286.6K ZVRA shares are owned by insiders